恩格列净治疗儿童糖原贮积病Ⅰb型的短期疗效
前瞻性开放标签单臂研究纳入4例基因诊断明确的GSDⅠb患儿,均存在中性粒细胞减少并接受恩格列净治疗,随访6至15个月。短期观察显示恩格列净可改善口腔溃疡、腹痛腹泻及反复感染症状,升高中性粒细胞绝对计数,降低血浆1,5AG浓度,未发生低血糖、泌尿系感染或肝肾功能异常等不良反应。
要点
- 恩格列净维持剂量范围为0.24~0.39 mg/(kg·d),4例患儿短期耐受性良好。
- 治疗后中性粒细胞绝对计数由0.48~0.84×10^9/L升至0.73~3.04×10^9/L,3例停用粒细胞集落刺激因子。
- 2例患儿血浆1,5AG分别由46.3 mg/L降至9.6 mg/L、由56.1 mg/L降至15.0 mg/L。
核心结论
- 短期观察中恩格列净可改善GSDⅠb患儿口腔溃疡、腹痛腹泻及反复感染症状,增加中性粒细胞计数,降低血浆1,5AG浓度,安全性良好。
研究设计与样本
- 前瞻性开放标签单臂研究,纳入2020年12月至2022年12月北京协和医院儿科4例基因诊断明确且存在中性粒细胞减少的GSDⅠb患儿。
- 恩格列净维持剂量范围为0.24~0.39 mg/(kg·d),随访时间分别为15、15、12和6个月。
主要发现
- 所有患儿用药1~4个月后口腔溃疡改善,例2、3、4腹泻及腹痛频率改善时间分别为1、2、3个月。
- 中性粒细胞绝对计数分别由0.84×10^9、0.50×10^9、0.48×10^9、0.48×10^9/L升至1.48×10^9、3.04×10^9、1.10×10^9、0.73×10^9/L。
- 3例患儿停用粒细胞集落刺激因子,1例减量。
- 例2血浆1,5AG由46.3 mg/L降至9.6 mg/L,例3由56.1 mg/L降至15.0 mg/L。
- 4例患儿均未发生低血糖、泌尿系感染、肝肾功能异常等不良反应。
临床怎么用
- 对存在中性粒细胞减少的GSDⅠb患儿,恩格列净可作为短期改善口腔溃疡、腹痛腹泻、反复感染及中性粒细胞减少的选项之一。
- 用药期间需监测中性粒细胞计数及血浆1,5AG浓度,并随访低血糖、泌尿系感染及肝肾功能等不良反应。
局限性
- 本研究为单臂开放标签设计,样本量仅4例,缺乏对照组,随访时间较短,结论需更大样本及更长随访验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Objective: To analyze the short-time efficacy of empagliflozin in the treatment of glycogen storage disease type Ⅰb (GSD Ⅰb). Methods: In this prospective open-label single-arm study, the data of 4 patients were collected from the pediatric department in Peking Union Medical College Hospital from December 2020 to December 2022. All of them were diagnosed by gene sequencing and had neutropenia. These patients received empagliflozin treatment. Their clinical symptoms such as height and weight increase, abdominal pain, diarrhea, oral ulcer, infection times, and drug applications were recorded at 2 weeks, 1 month, 2 months, 3 months, 6 months, 9 months, 12 months, and 15 months after treatment to assess the therapeutic effect. The liquid chromatography-tandem mass spectrometry method was used to monitor the changes in 1, 5-anhydroglucitol (1, 5AG) concentration in plasma. At the same time, adverse reactions such as hypoglycemia and urinary tract infection were closely followed up and monitored. Results: The 4 patients with GSD Ⅰb were 15, 14, 4 and 14 years old, respectively at the beginning of empagliflozin treatment, and were followed up for 15, 15, 12 and 6 months, respectively. Maintenance dose range of empagliflozin was 0.24-0.39 mg/(kg·d). The frequency of diarrhea and abdominal pain decreased in cases 2, 3, and 4 at 1, 2 and 3 months of treatment, respectively. Their height and weight increased at different degrees.The absolute count of neutrophils increased from 0.84×109, 0.50×109, 0.48×109, 0.48×109/L to 1.48×109, 3.04×109, 1.10×109, 0.73×109/L, respectively. Granulocyte colony-stimulating factor was gradually reduced in 1 patients and stopped in 3 patient. Plasma 1, 5 AG levels in 2 children were significantly decreased after administration of empagliflozin (from 46.3 mg/L to 9.6 mg/L in case 2, and from 56.1 mg/L to 15.0 mg/L in case 3). All 4 patients had no adverse reactions such as hypoglycemia, abnormal liver or kidney function, or urinary system infection. Conclusion: In short-term observation, empagliflozin can improve the symptoms of GSD Ⅰb oral ulcers, abdominal pain, diarrhea, and recurrent infection, also can alleviate neutropenia and decrease 1, 5AG concentration in plasma, with favorable safety. 目的: 探讨恩格列净治疗糖原贮积病Ⅰb型(GSDⅠb)患儿的短期效果。 方法: 前瞻性开放标签单臂研究。选取2020年12月至2022年12月于北京协和医院儿科就诊的4例基因诊断明确GSDⅠb患儿为研究对象,所有患儿均存在中性粒细胞减少并接受恩格列净治疗,分别于治疗前及治疗后2周、治疗后1、2、3、6、9、12、15个月收集患儿身高、体重;腹痛腹泻、口腔溃疡、感染次数等临床症状;药物治疗情况;中性粒细胞计数变化,评估治疗疗效。应用液相色谱串联质谱法监测血浆中1,5-脱水葡萄糖醇(1,5AG)浓度的变化。并对低血糖、尿路感染等不良反应进行监测。 结果: 4例GSDⅠb患儿开始恩格列净治疗时年龄分别为15、14、4、14岁,随访时间分别为15、15、12、6个月。维持用药剂量范围为0.24~0.39 mg/(kg·d)。所有患儿在用药1~4个月后口腔溃疡得到改善;例2、3、4腹泻及腹痛频率改善时间分别为1、2、3个月。身高、体重不同程度增加,中性粒细胞绝对计数分别由0.84×109、0.50×109、0.48×109、0.48×109/L升至1.48×109、3.04×109、1.10×109、0.73×109/L,3例患儿停用粒细胞集落刺激因子,1例患儿减量。2例患儿血浆1,5AG在恩格列净用药后均明显降低(例2由46.3 mg/L下降至9.6 mg/L,例3由56.1 mg/L下降至15.0 mg/L)。4例患儿均未发生低血糖、泌尿系感染、肝肾功能异常等不良反应。 结论: 短期应用观察中恩格列净可改善GSDⅠb患儿口腔溃疡、腹痛腹泻、反复感染症状,增加中性粒细胞计数,降低血浆中1,5AG浓度,未见低血糖、泌尿系感染等不良反应。.
引用
- Jiang JJ, Zheng X, Ma MS, et al. [Short-term efficacy of empagliflozin in children with glycogen storage disease type Ⅰb]. Zhonghua Er Ke Za Zhi. 2023. PMID: 37312462. doi:10.3760/cma.j.cn112140-20230131-00067
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。